Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 292


Pharmacologic Therapy of Type 2 Diabetes.

Wright JJ, Tylee TS.

Med Clin North Am. 2016 Jul;100(4):647-63. doi: 10.1016/j.mcna.2016.03.014. Review.


Small-volume potentiometric titrations: EPR investigations of Fe-S cluster N2 in mitochondrial complex I.

Wright JJ, Salvadori E, Bridges HR, Hirst J, Roessler MM.

J Inorg Biochem. 2016 Apr 20. pii: S0162-0134(16)30111-8. doi: 10.1016/j.jinorgbio.2016.04.025. [Epub ahead of print]


Re-engineering a NiFe hydrogenase to increase the H2 production bias while maintaining native levels of O2 tolerance.

Flanagan LA, Wright JJ, Roessler MM, Moir JW, Parkin A.

Chem Commun (Camb). 2016 Apr 8. [Epub ahead of print]


A Novel Itc Approach: Matching Patient-Level Data To Study-Level Summary Means And Variances.

Alsop JC, Regnier SA, Wright JJ.

Value Health. 2015 Nov;18(7):A687. doi: 10.1016/j.jval.2015.09.2543. Epub 2015 Oct 20. No abstract available.


Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer.

Tolaney SM, Tan S, Guo H, Barry W, Van Allen E, Wagle N, Brock J, Larrabee K, Paweletz C, Ivanova E, Janne P, Overmoyer B, Wright JJ, Shapiro GI, Winer EP, Krop IE.

Invest New Drugs. 2015 Oct;33(5):1108-14. doi: 10.1007/s10637-015-0269-8. Epub 2015 Jul 1.


Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.

Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE.

Haematologica. 2015 Sep;100(9):1172-9. doi: 10.3324/haematol.2015.125849. Epub 2015 May 28.


Catholics, science and civic culture in Victorian Belfast.

Finnegan DA, Wright JJ.

Br J Hist Sci. 2015 Jun;48(2):261-87. doi: 10.1017/S0007087414000594.


A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer.

Do K, Cao L, Kang Z, Turkbey B, Lindenberg ML, Larkins E, Holkova B, Steinberg SM, Raffeld M, Peer CJ, Figg WD, Eugeni M, Jacobs P, Choyke P, Wright JJ, Doroshow JH, Kummar S.

Clin Colorectal Cancer. 2015 Sep;14(3):154-61. doi: 10.1016/j.clcc.2015.02.007. Epub 2015 Mar 7.


Female sexual dysfunction.

Wright JJ, O'Connor KM.

Med Clin North Am. 2015 May;99(3):607-28. doi: 10.1016/j.mcna.2015.01.011. Epub 2015 Mar 6. Review.


A phase i study of DMS612, a novel bifunctional alkylating agent.

Appleman LJ, Balasubramaniam S, Parise RA, Bryla C, Redon CE, Nakamura AJ, Bonner WM, Wright JJ, Piekarz R, Kohler DR, Jiang Y, Belani CP, Eiseman J, Chu E, Beumer JH, Bates SE.

Clin Cancer Res. 2015 Feb 15;21(4):721-9. doi: 10.1158/1078-0432.CCR-14-1333. Epub 2014 Dec 2.


Möbius-strip-like columnar functional connections are revealed in somato-sensory receptive field centroids.

Wright JJ, Bourke PD, Favorov OV.

Front Neuroanat. 2014 Oct 31;8:119. doi: 10.3389/fnana.2014.00119. eCollection 2014.


Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.

Karovic S, Wen Y, Karrison TG, Bakris GL, Levine MR, House LK, Wu K, Thomeas V, Rudek MA, Wright JJ, Cohen EE, Fleming GF, Ratain MJ, Maitland ML.

Clin Pharmacol Ther. 2014 Jul;96(1):27-35. doi: 10.1038/clpt.2014.63. Epub 2014 Mar 17.


Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.

Schwandt A, von Gruenigen VE, Wenham RM, Frasure H, Eaton S, Fusco N, Fu P, Wright JJ, Dowlati A, Waggoner S.

Invest New Drugs. 2014 Aug;32(4):729-38. doi: 10.1007/s10637-014-0078-5. Epub 2014 Mar 12.


Hypotheses about the psychological benefits of horses.

Kendall E, Maujean A, Pepping CA, Wright JJ.

Explore (NY). 2014 Mar-Apr;10(2):81-7. doi: 10.1016/j.explore.2013.12.001. Epub 2013 Dec 17.


Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach.

Ocean AJ, Christos P, Sparano JA, Shah MA, Yantiss RK, Cheng J, Lin J, Papetti M, Matulich D, Schnoll-Sussman F, Besanceney-Webler C, Xiang J, Ward M, Dilts KT, Keresztes R, Holloway S, Chen EX, Wright JJ, Lane ME.

Invest New Drugs. 2014 Jun;32(3):542-8. doi: 10.1007/s10637-014-0070-0. Epub 2014 Feb 15.


A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers.

Denlinger CS, Meropol NJ, Li T, Lewis NL, Engstrom PF, Weiner LM, Cheng JD, Alpaugh RK, Cooper H, Wright JJ, Cohen SJ.

Clin Colorectal Cancer. 2014 Jun;13(2):81-6. doi: 10.1016/j.clcc.2013.12.005. Epub 2014 Jan 4.


Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

Widemann BC, Dombi E, Gillespie A, Wolters PL, Belasco J, Goldman S, Korf BR, Solomon J, Martin S, Salzer W, Fox E, Patronas N, Kieran MW, Perentesis JP, Reddy A, Wright JJ, Kim A, Steinberg SM, Balis FM.

Neuro Oncol. 2014 May;16(5):707-18. doi: 10.1093/neuonc/nou004. Epub 2014 Feb 4.


Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.

Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL.

Neuro Oncol. 2014 Apr;16(4):567-78. doi: 10.1093/neuonc/not247. Epub 2014 Jan 26.


A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium.

Laurie SA, Goss GD, Shepherd FA, Reaume MN, Nicholas G, Philip L, Wang L, Schwock J, Hirsh V, Oza A, Tsao MS, Wright JJ, Leighl NB.

Clin Lung Cancer. 2014 Jan;15(1):52-7. doi: 10.1016/j.cllc.2013.08.001. Epub 2013 Oct 26.


A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.

Schelman WR, Traynor AM, Holen KD, Kolesar JM, Attia S, Hoang T, Eickhoff J, Jiang Z, Alberti D, Marnocha R, Reid JM, Ames MM, McGovern RM, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH.

Invest New Drugs. 2013 Dec;31(6):1539-46. doi: 10.1007/s10637-013-0029-6. Epub 2013 Oct 10.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk